GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Debt-to-EBITDA

VGI Health Technology (XNEC:VTL) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

VGI Health Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology's annualized EBITDA for the quarter that ended in . 20 was A$0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for VGI Health Technology's Debt-to-EBITDA or its related term are showing as below:

XNEC:VTL's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.38
* Ranked among companies with meaningful Debt-to-EBITDA only.

VGI Health Technology Debt-to-EBITDA Historical Data

The historical data trend for VGI Health Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Debt-to-EBITDA Chart

VGI Health Technology Annual Data
Trend
Debt-to-EBITDA

VGI Health Technology Semi-Annual Data
Debt-to-EBITDA

Competitive Comparison of VGI Health Technology's Debt-to-EBITDA

For the Biotechnology subindustry, VGI Health Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VGI Health Technology's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Debt-to-EBITDA falls into.



VGI Health Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

VGI Health Technology's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

VGI Health Technology's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.


VGI Health Technology  (XNEC:VTL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


VGI Health Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology Headlines

No Headlines